Global Anticancer monoclonal antibodies Market Size study & Forecast, by Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types), By Application (Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications), By End User (Hospitals, Research Institutes, Other End Users) and Regional Analysis, 2023-2030
Global Anticancer monoclonal antibodies Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Anti-cancer monoclonal antibodies are made to specifically target and bind to antigens expressed on cancer cells or in the tumour microenvironment. These antibodies can influence the body's immunological response to cancer cells, suppress tumour development, boost the immune system's ability to fight cancer, and transport cytotoxic chemicals directly to tumour cells, among other processes. The market for anti-cancer MAbs is being driven by factors such as the rising incidence and prevalence of cancer in the globe, the expanding knowledge of cancer biology and the discovery of novel therapeutic targets, and improvements in biotechnology and antibody engineering methods.
The American Society of Clinical Oncology predicts that by the end of 2022, there have been 1.9 million cancer diagnoses and 609,360 cancer-related deaths in the United States. Additionally, estimations from the same source suggested that 176,000 people had multiple myeloma diagnoses globally in 2020. More than 34,000 people given a multiple myeloma diagnosis in 2022, and more than 12,000 people expected to pass away in the United States. More than a dozen monoclonal antibodies have received FDA approval in the last few years to treat different cancers. Furthermore, GamaMabs Pharma SA was purchased by Exelixis Inc., a USD 5 million genomics-based drug development company, in May 2021. Exelixis Inc. intends to expand its current therapeutic product range of GamaMabs and related manufacturing cell lines by acquiring GamaMabs' AMHR2 antibody technology. The biotechnology company GamaMabs Pharma SA is established in France and is dedicated to creating novel monoclonal antibodies for the treatment of solid tumours. However, the high cost of treatment and side Effects and Safety Concerns stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Anticancer monoclonal antibodies Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is the leading region owing to rising strategies such as partnership and collaboration. However, Asia Pacific is expected to be the fastest growing region due to the increasing number of international and national collaborations among entities, especially those in developed and developing countries, which is expected to propel the market.
Major market player included in this report are:Amgen Inc.
Bristol Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genmab AS
Novartis AG
Merck & Co., Inc.
GlaxoSmithKline plc
Johnson & Johnson Corp.
AbbVie, Inc.
Recent Developments in the Market:In May 2022, PHESGO was introduced by Roche Holding AG, a pharmaceutical business located in Switzerland. Pertuzumab, trastuzumab, and hyaluronidase-zzxf, or PHESGO, is a novel monoclonal antibody (mAb) combination therapy for early breast cancer that is HER2-positive. The two monoclonal antibodies (mAbs) pertuzumab and trastuzumab, along with the enzyme hyaluronidase, are administered subcutaneously (under the skin).
In 2021, GamaMabs Pharma SA was purchased by Exelixis Inc., a genomics-based medicine discovery business with headquarters in the US, for USD 5 million. Exelixis Inc. intends to expand its current therapeutic product range of GamaMabs and related manufacturing cell lines by acquiring GamaMabs' AMHR2 antibody technology.
Global Anticancer monoclonal antibodies Market Report Scope:Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Type, Application, End User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which expected to define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
The detailed segments and sub-segment of the market are explained below: By Type:
Murine Antibodies
Chimeric Antibodies
Humanized Antibodies
Other Types
By Application:
Blood Cancer
Breast Cancer
Lung Cancer
Melanoma
Colorectal Cancer
Liver Cancer
Other Applications
By End User:
Hospitals
Research Institutes
Other End Users
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
Companies MentionedAmgen Inc.
Bristol Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genmab AS
Novartis AG
Merck & Co., Inc.
GlaxoSmithKline plc
Johnson & Johnson Corp.
AbbVie, Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.